Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and Alzheimer’s disease risk

We found that brain glucose metabolism is a notable determinant of cognitive decline progression, especially for Alzheimer's disease risk, providing quantifiable metabolic protection against decline. Our results demonstrate brain glucose hypometabolic findings from baseline FDG-PET as a precision biomarker for therapeutic stratification and support further interventions for cognitive preservation for further research, validation and development purposes that should be further evaluated and investigated in further clinical trials that may lead to better preventive and therapeutic benefits for cognitive functions preservation and prevention of cognitive decline process in high-risk individuals.

Authors

Institutions

Publication Details

Journal
The journal of nutrition health & aging
Published
2026-03-11
DOI
https://doi.org/10.1016/j.jnha.2026.100823
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and Alzheimer’s disease risk

James Milburn, Mustafa S. Alhasan, Seham Hamoud, Omar Alharthi et al.
The journal of nutrition health & aging
Dementia and Cognitive Impairment Research
article

Baseline FDG-PET Brain hypometabolism as a predictive biomarker of cognitive decline and Alzheimer’s disease risk

James Milburn, Mustafa S. Alhasan, Seham Hamoud, Omar Alharthi, Ayman S. Alhasan, Muhammed Amir Essibayi, Fabrício Stewan Feltrin, Dhairya A. Lakhani, Yasir Hassan Elhassan, Abdullah Almaghraby, Ahmed Y. Azzam, Mohammad Khalil, Sumit Singh, Hadeel A. Ghunaim
article en

Abstract

We found that brain glucose metabolism is a notable determinant of cognitive decline progression, especially for Alzheimer's disease risk, providing quantifiable metabolic protection against decline. Our results demonstrate brain glucose hypometabolic findings from baseline FDG-PET as a precision biomarker for therapeutic stratification and support further interventions for cognitive preservation for further research, validation and development purposes that should be further evaluated and investigated in further clinical trials that may lead to better preventive and therapeutic benefits for cognitive functions preservation and prevention of cognitive decline process in high-risk individuals.

The journal of nutrition health & agingVol. 30(5)
West Virginia University (US), University of Suffolk (GB), Albert Einstein College of Medicine (US), Montefiore Medical Center (US), King Abdulaziz University (SA), Umm al-Qura University (SA), Taibah University (SA), Ochsner Medical Center (US), Blanchette Rockefeller Neurosciences Institute (US), The University of Texas Southwestern Medical Center (US)
Zero hunger
Openalex Percentile: Top 35%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.